Pan-cancer analysis of whole genomes
- PMID: 32025007
- PMCID: PMC7025898
- DOI: 10.1038/s41586-020-1969-6
Pan-cancer analysis of whole genomes
Erratum in
-
Author Correction: Pan-cancer analysis of whole genomes.Nature. 2023 Feb;614(7948):E39. doi: 10.1038/s41586-022-05598-w. Nature. 2023. PMID: 36697834 Free PMC article. No abstract available.
Abstract
Cancer is driven by genetic change, and the advent of massively parallel sequencing has enabled systematic documentation of this variation at the whole-genome scale1-3. Here we report the integrative analysis of 2,658 whole-cancer genomes and their matching normal tissues across 38 tumour types from the Pan-Cancer Analysis of Whole Genomes (PCAWG) Consortium of the International Cancer Genome Consortium (ICGC) and The Cancer Genome Atlas (TCGA). We describe the generation of the PCAWG resource, facilitated by international data sharing using compute clouds. On average, cancer genomes contained 4-5 driver mutations when combining coding and non-coding genomic elements; however, in around 5% of cases no drivers were identified, suggesting that cancer driver discovery is not yet complete. Chromothripsis, in which many clustered structural variants arise in a single catastrophic event, is frequently an early event in tumour evolution; in acral melanoma, for example, these events precede most somatic point mutations and affect several cancer-associated genes simultaneously. Cancers with abnormal telomere maintenance often originate from tissues with low replicative activity and show several mechanisms of preventing telomere attrition to critical levels. Common and rare germline variants affect patterns of somatic mutation, including point mutations, structural variants and somatic retrotransposition. A collection of papers from the PCAWG Consortium describes non-coding mutations that drive cancer beyond those in the TERT promoter4; identifies new signatures of mutational processes that cause base substitutions, small insertions and deletions and structural variation5,6; analyses timings and patterns of tumour evolution7; describes the diverse transcriptional consequences of somatic mutation on splicing, expression levels, fusion genes and promoter activity8,9; and evaluates a range of more-specialized features of cancer genomes8,10-18.
Comment in
-
Global genomics project unravels cancer's complexity at unprecedented scale.Nature. 2020 Feb;578(7793):39-40. doi: 10.1038/d41586-020-00213-2. Nature. 2020. PMID: 32025004 No abstract available.
References
MeSH terms
Substances
Grants and funding
- 25813/CRUK_/Cancer Research UK/United Kingdom
- 23433/CRUK_/Cancer Research UK/United Kingdom
- 27815/CRUK_/Cancer Research UK/United Kingdom
- R01 CA235162/CA/NCI NIH HHS/United States
- 23924/CRUK_/Cancer Research UK/United Kingdom
- U24 CA210950/CA/NCI NIH HHS/United States
- MC_UU_12009/11/MRC_/Medical Research Council/United Kingdom
- MC_U137961146/MRC_/Medical Research Council/United Kingdom
- 20952/CRUK_/Cancer Research UK/United Kingdom
- T32 GM008313/GM/NIGMS NIH HHS/United States
- 16942/CRUK_/Cancer Research UK/United Kingdom
- MC_UU_12022/2/MRC_/Medical Research Council/United Kingdom
- R35 GM127029/GM/NIGMS NIH HHS/United States
- U24 CA211000/CA/NCI NIH HHS/United States
- P30 ES010126/ES/NIEHS NIH HHS/United States
- P30 CA016672/CA/NCI NIH HHS/United States
- 23916/CRUK_/Cancer Research UK/United Kingdom
- MC_UU_00016/11/MRC_/Medical Research Council/United Kingdom
- 22720/CRUK_/Cancer Research UK/United Kingdom
- MC_UU_00007/16/MRC_/Medical Research Council/United Kingdom
- MR/L008963/1/MRC_/Medical Research Council/United Kingdom
- R01 GM109031/GM/NIGMS NIH HHS/United States
- R01 HG007069/HG/NHGRI NIH HHS/United States
- T32 HG002295/HG/NHGRI NIH HHS/United States
- U01 CA217842/CA/NCI NIH HHS/United States
- U24 CA180951/CA/NCI NIH HHS/United States
- R01 CA218668/CA/NCI NIH HHS/United States
- 22932/CRUK_/Cancer Research UK/United Kingdom
- 27176/CRUK_/Cancer Research UK/United Kingdom
- U24 CA210974/CA/NCI NIH HHS/United States
- 22131/CRUK_/Cancer Research UK/United Kingdom
- P01 CA240239/CA/NCI NIH HHS/United States
- R01 CA183793/CA/NCI NIH HHS/United States
- 26718/CRUK_/Cancer Research UK/United Kingdom
- P30 CA014236/CA/NCI NIH HHS/United States
- 18387/CRUK_/Cancer Research UK/United Kingdom
- 23917/CRUK_/Cancer Research UK/United Kingdom
- U24 CA210949/CA/NCI NIH HHS/United States
- U24 CA210969/CA/NCI NIH HHS/United States
- U24 CA210999/CA/NCI NIH HHS/United States
- 15874/CRUK_/Cancer Research UK/United Kingdom
- G1000729/MRC_/Medical Research Council/United Kingdom
- 14545/CRUK_/Cancer Research UK/United Kingdom
- UG1 CA233339/CA/NCI NIH HHS/United States
- 088177/WT_/Wellcome Trust/United Kingdom
- U24 CA210990/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
